Search Results - "Müller‐Wieland, Dirk"

Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM‐INSULIN randomized trial by Leiter, Lawrence A., Cariou, Bertrand, Müller‐Wieland, Dirk, Colhoun, Helen M., Del Prato, Stefano, Tinahones, Francisco J., Ray, Kausik K., Bujas‐Bobanovic, Maja, Domenger, Catherine, Mandel, Jonas, Samuel, Rita, Henry, Robert R.

“…Aims To investigate the efficacy and safety of alirocumab in participants with type 2 (T2D) or type 1 diabetes (T1D) treated with insulin who have elevated LDL…”
Get full text

Alirocumab vs usual lipid‐lowering care as add‐on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA randomized trial by Ray, Kausik K., Leiter, Lawrence A., Müller‐Wieland, Dirk, Cariou, Bertrand, Colhoun, Helen M., Henry, Robert R., Tinahones, Francisco J., Bujas‐Bobanovic, Maja, Domenger, Catherine, Letierce, Alexia, Samuel, Rita, Del Prato, Stefano

“…Aim To compare alirocumab, a proprotein convertase subtilisin‐kexin type 9 inhibitor, with usual care (UC) in individuals with type 2 diabetes (T2DM) and mixed…”
Get full text

Prevalence of obesity and cardiovascular disease in adults with type 2 diabetes and use of diabetes medication in Germany: A claims data study by Hennies, Nora, Görgens, Sven W., Killer, Jonas, Otto, Thorsten, Richter, Lena M., Müller‐Wieland, Dirk, Häckl, Dennis

“…Aims To identify the prevalence of cardiovascular disease (CVD) and obesity in patients with type 2 diabetes (T2D) in Germany and to evaluate if antidiabetic…”
Get full text

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes by Müller‐Wieland, Dirk, Kellerer, Monika, Cypryk, Katarzyna, Skripova, Dasa, Rohwedder, Katja, Johnsson, Eva, Garcia‐Sanchez, Ricardo, Kurlyandskaya, Raisa, Sjöström, C. David, Jacob, Stephan, Seufert, Jochen, Dronamraju, Nalina, Csomós, Katalin

“…Objective To compare the efficacy and safety of dapagliflozin and dapagliflozin plus saxagliptin vs glimepiride as add‐on to metformin in patients with type 2…”
Get full text

Age‐dependent prevalence of type 2 diabetes, cardiovascular risk profiles and use of diabetes drugs in Germany using health claims data by Otto, Thorsten, Diesing, Joanna, Borchert, Julia, Heitmann, Elke, C. Schloot, Nanette, Lebrec, Jeremie, Müller‐Wieland, Dirk, Haeckl, Dennis

“…Aims This study evaluates type 2 diabetes mellitus (T2DM) prevalence in Germany, focusing on patients at risk for, or with already established, cardiovascular…”
Get full text

Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial by Haluzík, Martin, Cheng, Alice, Müller‐Wieland, Dirk, Westerbacka, Jukka, Bosnyak, Zsolt, Lauand, Felipe, Melas‐Melt, Lydie, Karalliedde, Janaka, Rosenstock, Julio, Bolli, Geremia B.

“…Aims Chronic kidney disease (CKD) challenges diabetes management and is associated with increased cardiovascular morbidity and mortality. We examined whether…”
Get full text

Survey to estimate the prevalence of type 2 diabetes mellitus in hospital patients in Germany by systematic HbA1c measurement upon admission by Müller-Wieland, Dirk, Merkel, Martin, Hamann, Andreas, Siegel, Erhard, Ottillinger, Bertram, Woker, Rainer, Fresenius, Kristian

“…The objective of this survey was to estimate the prevalence of type 2 diabetes mellitus (T2DM) in hospitalised patients ≥55 years based on routine HbA1c…”
Get more information

Role of Brain Insulin Receptor in Control of Body Weight and Reproduction by Brüning, Jens C., Gautam, Dinesh, Burks, Deborah J., Gillette, Jennifer, Schubert, Markus, Orban, Paul C., Klein, Rüdiger, Krone, Wilhelm, Müller-Wieland, Dirk, Kahn, C. Ronald

“…Insulin receptors (IRs) and insulin signaling proteins are widely distributed throughout the central nervous system (CNS). To study the physiological role of…”
Get full text

Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials by Henry, Robert R., Müller‐Wieland, Dirk, Taub, Pam R., Bujas‐Bobanovic, Maja, Louie, Michael J., Letierce, Alexia, Ginsberg, Henry N.

“…Aims This analysis assessed the efficacy and safety of alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, in patients with or without…”
Get full text

critical comparison between two classical and a kit-based method for mitochondria isolation by Hartwig, Sonja, Feckler, Christian, Lehr, Stefan, Wallbrecht, Katrin, Wolgast, Heike, Müller-Wieland, Dirk, Kotzka, Jörg

“…Numerous protocols for isolation of mitochondria are available. Here, three methods for the isolation of intact mitochondria from mouse liver tissues are…”
Get full text

Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk by Müller-Wieland, Dirk, Leiter, Lawrence A, Cariou, Bertrand, Letierce, Alexia, Colhoun, Helen M, Del Prato, Stefano, Henry, Robert R, Tinahones, Francisco J, Aurand, Lisa, Maroni, Jaman, Ray, Kausik K, Bujas-Bobanovic, Maja

“…Type 2 diabetes mellitus (T2DM) is often associated with mixed dyslipidaemia, where non-high-density lipoprotein cholesterol (non-HDL-C) levels may more…”
Get full text

Definition, Classification and Diagnosis of Diabetes Mellitus by Petersmann, Astrid, Müller-Wieland, Dirk, Müller, Ulrich A, Landgraf, Rüdiger, Nauck, Matthias, Freckmann, Guido, Heinemann, Lutz, Schleicher, Erwin

Get more information

Lipodystrophies-Disorders of the Fatty Tissue by Knebel, Birgit, Müller-Wieland, Dirk, Kotzka, Jorg

“…Lipodystrophies are a heterogeneous group of physiological changes characterized by a selective loss of fatty tissue. Here, no fat cells are present, either…”
Get full text

Effectiveness and safety of insulin glargine 300 U/mL in insulin-naïve individuals according to diabetes duration: Results from the REALI European pooled data analysis by Gourdy, Pierre, Bonadonna, Riccardo C, Mauricio, Didac, Müller-Wieland, Dirk, Mauquoi, Celine, Vera, Carine, Bonnemaire, Mireille, Freemantle, Nick

“…To evaluate the effectiveness and safety of insulin glargine 300 U/mL (Gla-300) initiation according to diabetes duration (DD). We analysed patient-level data…”
Get full text

Mechanisms of Insulin Resistance in Primary and Secondary Nonalcoholic Fatty Liver by Jelenik, Tomas, Kaul, Kirti, Séquaris, Gilles, Flögel, Ulrich, Phielix, Esther, Kotzka, Jörg, Knebel, Birgit, Fahlbusch, Pia, Hörbelt, Tina, Lehr, Stefan, Reinbeck, Anna Lena, Müller-Wieland, Dirk, Esposito, Irene, Shulman, Gerald I, Szendroedi, Julia, Roden, Michael

“…Nonalcoholic fatty liver disease is associated with hepatic insulin resistance and may result primarily from increased hepatic de novo lipogenesis (PRIM) or…”
Get full text

Editorial: Adipose tissue dysfunction by Blüher, Matthias, Müller-Wieland, Dirk

Get full text

Clinical course of COVID-19 patients needing supplemental oxygen outside the intensive care unit by Daher, Ayham, Balfanz, Paul, Aetou, Maria, Hartmann, Bojan, Müller-Wieland, Dirk, Müller, Tobias, Marx, Nikolaus, Dreher, Michael, Cornelissen, Christian G.

“…Patients suffering from CVOID-19 mostly experience a benign course of the disease. Approximately 14% of SARS-CoV2 infected patients are admitted to a hospital…”
Get full text

Liver-specific expression of transcriptionally active SREBP-1c is associated with fatty liver and increased visceral fat mass by Knebel, Birgit, Haas, Jutta, Hartwig, Sonja, Jacob, Sylvia, Köllmer, Cornelia, Nitzgen, Ulrike, Muller-Wieland, Dirk, Kotzka, Jorg

“…The pathogenesis of fatty liver is not understood in detail, but lipid overflow as well as de novo lipogenesis (DNL) seem to be the key points of hepatocyte…”
Get full text

Elevated serum SDMA and ADMA at hospital admission predict in-hospital mortality of COVID-19 patients by Hannemann, Juliane, Balfanz, Paul, Schwedhelm, Edzard, Hartmann, Bojan, Ule, Johanna, Müller-Wieland, Dirk, Dahl, Edgar, Dreher, Michael, Marx, Nikolaus, Böger, Rainer

“…COVID-19 is a disease with a variable clinical course ranging from mild symptoms to critical illness, organ failure, and death. Prospective biomarkers may help…”
Get full text

Roles of the N- and C-termini of GLUT4 in endocytosis by Al-Hasani, Hadi, Kunamneni, Raghu K, Dawson, Kevin, Hinck, Cynthia S, Müller-Wieland, Dirk, Cushman, Samuel W

“…In insulin target cells, the predominantly expressed glucose transporter isoform GLUT4 recycles between distinct intracellular compartments and the plasma…”
Get full text